Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Early Bird Ends

DAYS

HOURS

MINUTES

SECONDS

Back to Agenda

Session 2 Track 2: Extrahepatic Delivery 1: Engineering LNPs and Ligand Conjugates for Oligonucleotide Delivery to the Kidney and Lung Tumors

Toxicologist

FDA, United States

Executive Director, Toxicology

Nimbus Therapeutics, United States

Session 2 Track 2: Extrahepatic Delivery 1: Engineering LNPs and Ligand Conjugates for Oligonucleotide Delivery to the Kidney and Lung Tumors

Have an account?